Anti-Human CD20 (Ocrelizumab) [RG-1594] - 25 mg

All|Recombinant Antibodies>Biosimilar Recombinant Antibodies|Primary Monoclonal Antibodies

2 - 8°C Wet Ice

CD20 is a transmembrane protein that is prominently present on the surface of B-cells fromthe early to mature stages, but notably absent on hematopoietic stem cells, pro-B cells, orplasma cells. Its significance lies in its role in B-cell functions such as activation anddifferentiation. It is a key target for monoclonal antibodies used in the treatment of B-cell-related diseases and autoimmune conditions. Monoclonal antibodies targeting CD20 havebeen widely used to treat B-cell lymphomas, leukemias, and autoimmune diseases likerheumatoid arthritis and systemic lupus erythematosus. These antibodies work by selectivelytargeting and depleting B-cells that express CD20, thereby modulating the immune responseand reducing inflammation. This targeted approach has shown promising results in managingvarious B-cell disorders and has significantly improved the prognosis for patients with theseconditions1, 2. RG 1594, also known as ocrelizumab, is a humanized monoclonal antibody that targetsCD20, a protein found on the surface of B cells. By binding to CD20, ocrelizumab helps inthe depletion of B cells, which are believed to play a role in the development of sclerosis.This therapeutic approach has been found to be effective in reducing the progression ofdisability and lowering the frequency of relapses in patients with multiple sclerosis (MS)3-8.

≥ 5.0 mg/ml

CD20 is primarily expressed on the surface of B lymphocytes, including both normal and malignant B-cells.